Dr Alan Cohen joins MAP Pharmaceuticals
This article was originally published in Scrip
Dr Alan Cohen has joined MAP Pharmaceuticals(US) as vice-president of clinical development and medical affairs, pulmonary. He will oversee development and execution of the company's paediatric asthma clinical programme, including Phase III trials for Unit Dose Budesonide. Dr Cohen has more than 20 years' therapeutic, clinical and medical experience and most recently served as chief medical officer and vice-president of global medical affairs, safety and pharmacovigilance at Jazz Pharmaceuticals.